Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J. Liang X, et al. J Gastroenterol Hepatol. 2015 Apr;30(4):748-55. doi: 10.1111/jgh.12835. J Gastroenterol Hepatol. 2015. PMID: 25352300 Clinical Trial.
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Fan R, et al. Gut. 2016 Feb;65(2):313-20. doi: 10.1136/gutjnl-2014-308546. Epub 2015 Jan 13. Gut. 2016. PMID: 25586058 Free PMC article. Clinical Trial.
Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
Sun J, Ding H, Chen G, Wang G, Wei L, Zhang J, Xie Q, Wan M, Tang H, Chen S, Gao Z, Wang Y, Zhang D, Huang W, Sheng J, Ning Q, Yang D, Lu J, Pan C, Yang Y, Wang J, Sun C, Wang Q, Hou J. Sun J, et al. BMC Gastroenterol. 2019 May 2;19(1):65. doi: 10.1186/s12876-019-0981-5. BMC Gastroenterol. 2019. PMID: 31046700 Free PMC article. Clinical Trial.
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. Sun J, et al. Hepatology. 2014 Apr;59(4):1283-92. doi: 10.1002/hep.26885. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24382690 Clinical Trial.
Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.
Cheng J, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Mohamed R, Guan R, Lee TH, Chang WH, Zhenfei H, Ye Z, Xu D. Cheng J, et al. J Clin Virol. 2014 Dec;61(4):509-16. doi: 10.1016/j.jcv.2014.08.008. Epub 2014 Aug 18. J Clin Virol. 2014. PMID: 25200354 Free article. Clinical Trial.
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Hou FQ, et al. Among authors: wan mb. Theranostics. 2015 Jan 1;5(3):218-26. doi: 10.7150/thno.10636. eCollection 2015. Theranostics. 2015. PMID: 25553110 Free PMC article. Clinical Trial.
HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.
Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Xu D, Dong P, Wang Q, Wang J, Bognar FA, Xu D, Cheng J. Yang S, et al. Virol J. 2016 Oct 28;13(1):180. doi: 10.1186/s12985-016-0640-1. Virol J. 2016. PMID: 27793166 Free PMC article. Clinical Trial.
54 results